ICBMT 2021 International Congress of BMT 2021 26th annual congress of ksbmt Advancing HSCT through Virtual Collaboration August 26(Thu) – 28(Sat), 2021 VIRTUAL

News & Notice

News & Notices

Video

Invited Speakers

prev next
  • PS Making Sense of CAR-T Cell Therapy for Lymphoma David G Maloney Fred Hutchinson Cancer Research Center, USA CV Abstract
  • PL01 NGS-based MRD Monitoring Pre- and Post-allogeneic HSCT for AML Michael Heuser MHH Hospital, Germany CV Abstract
  • PL01 Conditioning Intensity of Allogeneic Transplantation for AML with MRD Christopher S. Hourigan NIH, USA CV Abstract
  • PL02 Engineering and Design for Next Generation CAR-T Cells Sham Mailankody MSKCC, USA CV Abstract
  • PL03 Development and Application of Machine Learning in Hematopoietic Stem Cell Transplantation Yasuyuki Arai Kyoto University, Japan CV Abstract
  • PL03 Current Statistical Issues in Hematopoietic Cell Transplantation Haesook T. Kim Dana-Farber Cancer Institute, USA CV Abstract
  • SS01 High Throughput Single Cell Analysis in AML Koichi Takahashi MDACC, USA CV Abstract
  • SS01 Therapeutic Implications in AML using Prospective Genomic Profiling Omar Abdel-Wahab MSKCC, USA CV Abstract
  • SS01 Clonal Hematopiesis of Indeterminate Potential in Transplantation Kyoung Ha Kim Soonchunhyang University Hospital, Korea CV Abstract
  • SS02 FLT3 Inhibitor Maintenance Therapy after Allogeneic HSCT in FLT3 Mutated AML Richard T. Maziarz Oregon Health and Science University, USA CV Abstract
  • SS02 Maintenance Therapy (Hypomethylating Agents, Bcl2-Inhibitor, Check Point Inhibitors, and Other Novel Drugs) after Allogeneic HSCT in AML and MDS Tapan Kadia MDACC, USA CV Abstract
  • SS02 Treatment Strategies after Allogeneic HSCT in Relapsed ALL Ik-Chan Song Chungnam National University College of Medicine, Korea CV Abstract
  • SS03 Current Ultimate Choice for Conditioning Regimens Christina Peters St. Anna Children’s Hospital, Austria CV Abstract
  • SS03 HSCT Incorporation with Non-Traditional Agents: Clofarabine, Treosulfan Franca Fagioli The University of Turin, Italy CV Abstract
  • SS03 Treatment after Failure of CD-19 Directed Therapy Nirali N. Shah National Cancer Institute, USA CV Abstract
  • SS04 Mass Spectrometry for Detection of Minimal Residual Disease in Multiple Myeloma Noemi Puig University Hospital of Salamanca, Spain CV Abstract
  • SS04 The Role of Tandem Autologous Transplantation for High Risk Multiple Myeloma Hyeon-Seok Eom National Cancer Center, Korea CV Abstract
  • SS04 CAR T in Relapsed/Refractory MM” Versus “CAR T in High Risk Nina Shah The University of California San Francisco, USA CV Abstract
  • SS05 Treosulfan Based Conditioning for Nonmalignant Diseases Ho Joon Im University of Ulsan College of Medicine, Korea CV Abstract
  • SS05 HSCT and Gene Therapy for Primary Immunodeficiency Andrew Gennery Newcastle University, UK CV Abstract
  • SS05 Optimizing the Conditioning Regimen of HSCT for Acquired Bone Marrow Failure in Children Nao Yoshida Japanese Red Cross Nagoya First Hospital, Japan CV Abstract
  • SS05 Bridge to Transplantation for Refractory HLH Michael B Jordan Cincinnati Children's Hospital Medical Center, USA CV Abstract
  • SS06 Ibrutinib and Other B Cell Directed Therapy in Chronic GVHD Corey Cuttler Dana-Farber Cancer Institute, USA CV Abstract
  • SS06 Ruxolitinib for GVHD Management Robert Zeiser University Medical Center Freiburg, Germany CV Abstract
  • SS06 Intestinal Goblet Cell and IL-25 in Intestinal GVHD Takanori Teshima Hokkaido University Graduate School of Medicine, Japan CV Abstract
  • SS07 CAR-NK Cells: A Promising Cellular Immunotherapy for Hematologic Malignancies Jianhua Yu City of Hope National Medical Center, USA CV Abstract
  • SS07 Adoptive T-Cell Immunotherapy- Experiences in Preclinical and Clinical Studies Tai-Gyu Kim The Catholic University of Korea, Korea CV Abstract
  • SS07 Novel Immunotherapeutic Approaches with Antibody Drugs Hermann Einsele University Hospital Würzburg, Germany CV Abstract
  • SS08 Haploidentical Transplantation with PTCy for SAA Régis Peffault de Latour Saint-Louis Hospital, France CV Abstract
  • SS08 Haploidentical Transplantation with ATG for SAA Sung-Eun Lee The Catholic University of Korea,Korea CV Abstract
  • SS08 Immunosuppressive Therapy Versus Haploidentical Transplantation in Adults with SAA Xiao jun Huang Peking University Institute of Hematology, China CV Abstract
  • SS09 'Off the shelf' CAR-T Cells for Relapsed Refractory Lymphoma and MM Sattva S Neelapu The University of Texas M.D. Anderson Cancer Center, USA CV Abstract
  • SS09 Use of CAR -T Cells in Allogeneic Stem Cell Transplantation Peggy Lu Lu Daopei hospital, China CV Abstract
  • SS09 Real World Experience of CAR-T Cells in Korea Won Seog Kim Sungkyunkwan University School of Medicine, Korea CV Abstract
  • SS10 Autologous Stem Cell Transplantation for Aggressive B-cell Lymphomas in the Frontline Setting: Current Controversies and Advances Narendranath Epperla The Ohio State University Comprehensive Cancer Center, USA CV Abstract
  • SS10 High Dose Therapy and Autologous Stem Cell Transplantation in Patients with Indolent Lymphoma Julie M. Vose University of Nebraska Medical Center, USA CV Abstract
  • SS10 The Role of Allogeneic Stem Cell Transplantation for Relapsed and Refractory Lymphoma in the Era of CAR-T Cell Therapy Youngwoo Jeon The Catholic University of Korea, Korea CV Abstract
  • SS11 Comparison of Allogeneic Stem Cell Transplantation from Matched Unrelated Donor (URD) and Haploidentical Family Donor (HFD) in Adults with Hematological Malignancies Focusing on Acute Leukemia Arnon Nagler Tel Aviv University, Israel CV Abstract
  • SS11 Cord Blood Versus Haploidentical Stem Cell Transplantation for Hematological Malignancies Jae-Ho Yoon The Catholic University of Korea, Korea CV Abstract
  • SS11 Unrelated Donor vs Haploidentical αβ T-cell- and B-cell-depleted HSCT in Children with Acute Leukemia Alice Bertaina Stanford School of Medicine, USA CV Abstract
  • SS12 Prophylactic/preemptive DLI: Real World Experience Xiao jun Huang Peking University Institute of Hematology, China CV Abstract
  • SS12 Therapeutic DLI in Relapsed/Refractory Hematologic Malignancy Bhagirathbhai Dholaria Vanderbilt University Medical Center , USA CV Abstract
  • SS12 PTCY Based Haplo and DLI Hyoung Jin Kang Seoul National University College of Medicine, Korea CV Abstract
  • SS13 Error-corrected Next Generation Sequencing to Detect MRD in AML Nikhil Patkar Tata Memorial Centre, India CV Abstract
  • SS13 Haploidentical CD19 CAR-T Cell for Treatment of Relapsed Refractory ALL Suradej Hongeng Mahidol University, Thailand CV Abstract
  • SS13 Hematopoietic Stem Cell Transplantation Have Relation with Clinical Phenotype of Fanconi Anemia Patients: Iranian Experience Amir Ali Hamidieh Tehran University of Medical Sciences, Iran CV Abstract
  • JS01 Infectious Complication: CMV Infection Yae Jean Kim Sungkyunkwan University School of Medicine, Korea CV Abstract
  • JS01 Infectious Complication: HHV-6 Infection in Japan Masao Ogata Oita University, Japan CV Abstract
  • JS01 Gut GVHD-microbiome Dong-Mi Shin Seoul National University College of Medicine, Korea CV Abstract
  • JS01 Intestinal Dysbiosis and GVHD; Preclinical and Clinical Findings Daigo Hashimoto Hokkaido University, Korea CV Abstract
  • JS02 Bridging Therapy To Allo-HSCT (Novel Agent before and after Allo-HSCT) Ali Bazarbachi American University of Beirut, Lebanon CV Abstract
  • JS02 Novel Agents for Relapsed or Refractory Hodgkin Lymphoma in Korea Won Seog Kim Sungkyunkwan University School of Medicine, Korea CV Abstract
  • JS02 PTCy in Haplo-HSCT in HL Anna Sureda Institut Català d'Oncologia, Spain CV Abstract
  • JS02 Allo-HSCT in Hodgkin Lymphoma in Korea Seok-Goo Cho The Catholic University of Korea, Korea CV Abstract
  • JS03 The Role of Flow-, PCR- and NGS-based MRD in guiding HCT and CAR T-cell therapy for Acute Lymphoblastic Leukemia Michael Pulsipher Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, USA CV Abstract
  • JS03 NGS-based MRD Before and After Allogeneic HCT in Myeloid Neoplasms Myungshin Kim The Catholic University of Korea, Korea CV Abstract
  • JS03 Molecular Measurable Residual Disease for AML Patients Who Undergoing HSCT Byung Sik Cho The Catholic University of Korea, Korea CV Abstract
  • JS04 CAR-T Cell Therapy on Pancreatic Cancer John Rasko Royal Prince Alfred Hospital, Australia CV Abstract
  • JS04 Strategies of CAR-T Cell Therapy to Overcome Challenges in Solid Tumors Baeckseung Lee MJCELLBIO, Korea CV Abstract
  • JS04 Development of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells against Malignant Glioma Song-Jae Lee CellabMED Inc., Korea CV Abstract
  • JS05 Second Malignancies after Allo-HST & Auto-HSCT in Turkey Huseyin Saffet Bekoz Medipol University Hospital, Turkey CV Abstract
  • JS05 Second Malignancies after Allo-HSCT & Auto-HSCT in Korea Seung-Hwan Shin The Catholic University of Korea, Korea CV Abstract
  • ES01 VOD/SOS: Prophylactic, Preemptive and Curative Treatment Paul Richardson Dana-Farber Cancer Institute, USA CV Abstract
  • ES01 Transplantation-associated TMA: Pathophysiology, Risk Factors and Management Christopher Dandoy Cincinnati Children’s Hospital Medical Center , USA CV Abstract
  • ES01 Management of Hemorrhagic Cystitis Ja Min Byun Seoul National University College of Medicine, Korea CV Abstract
  • ES02 Nutritional Management in Patients Treated with Stem Cell Transplantation Ka-Won Kang Korea University College of Medicine, Korea CV Abstract
  • ES02 Management of Long-Term Endocrine Complications after Hematopoietic Stem Cell Transplantation Jin-Ho Choi University of Ulsan College of Medicine, Korea CV Abstract
  • ES02 Fertility Preservation and Reproductive Health in Allogeneic Hematopoietic Stem Cell Transplantation Seungmin Hahn Yonsei University College of Medicine, Korea CV Abstract
  • ES03 The Role of Stem Cell Transplantation for WM Masatoshi Sakurai Keio University, Japan CV Abstract
  • ES03 HSCT in Patients with Blastic Plasmacytic Dendritic Cell Neoplasm Ji Hyun Lee Dong-A University, Korea CV Abstract
  • ES03 Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis. For Whom, When and How? Chul Won Jung Sungkyunkwan University School of Medicine, Korea CV Abstract
  • ES04 Germline Predisposition: an Emerging Issue in Donor Selection for HSCT Lucy Godley The University of Chicago, USA CV Abstract
  • ES04 Chimerism Monitoring Using NGS Assay Hyun-Ji Lee Pusan National University Yangsan Hospital, Korea CV Abstract
  • ES04 NGS-based HLA Typing Yun Ji Hong Seoul National University College of Medicine, Korea CV Abstract
  • ES05 Statistical Methods in HSCT Hwa Jung Kim Ulsan University College of Medicine, Korea CV Abstract
  • ES05 Designing Clinical Studies in the HSCT Setting Seokyung Hahn Seoul National University College of Medicine, Korea CV Abstract
  • NS01 Current Status of Blood and Marrow Transplantation in Korea Hye youn Lee Seoul National University College of Medicine, Korea CV Abstract
  • NS01 The Role of Coordinator Nurses in Field of Hematopoietic Stem Cell Transplantation Minjin Choi Sungkyunkwan University School of Medicine, Korea CV Abstract
  • NS02 Updated View on the Treatment of Hemato-Oncology Ja Min Byun Seoul National University College of Medicine, Korea CV Abstract
  • RL01 Current Progress in Cellular Immunotherapy for Hematologic Malignancies Sung-Hoon Jung Chonnam National University Hwasun Hospital, Korea CV Abstract
  • RL01 Understanding the Role of Genetics in Hematologic Malignanci Saeam Shin Yonsei University, Korea CV Abstract
  • RL01 Long-term Management in Pediatric Patients after HSCT Eu Jeen Yang Pusan National University School of Medicine, Korea CV Abstract
  • CD01 TBA Yoon Seok Choi Ajou University School of Medicine, Korea CV Abstract
  • IS01 TBA Hawk Kim Gachon University College of Medicine, Korea CV Abstract
  • IS02 Optimizing Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Thomas Martin University of California San Francisco, USA CV Abstract
  • IS03 Elevating the CML Treatment Goals by Personalizing Treatment with Dasatinib Jeff Lipton University of Toronto, Canada CV Abstract
  • IS04 TBA Michael Dickinson Peter MacCallum Cancer Cantre, Australia CV Abstract
  • IS05 TBA Andrew Wei Monash University, Australia CV Abstract
  • IS06 TBA Youngil Koh Seoul National University College of Medicine, Korea CV Abstract
  • IS07 TBA Jun Ho Jang Sungkyunkwan University School of Medicine, Korea CV Abstract
  • IS08 CAR T-Cell Therapies for Multiple Myeloma: Where are We Now and What are the Key Issues? Thomas Martin University of California San Francisco, USA CV Abstract
  • IS09 Management of MRD Positive ALL Itaru Kato Kyoto University Hospital, Japan CV Abstract

Organized by

Supported by

Sponsors